
    
      The study has 3 periods: a screening phase, a double-blind, double-dummy treatment phase from
      the time of randomization to the 26 weeks visit, and an open-label treatment phase of
      approximately 12 month duration, where participants will continue treatment with the same
      study drug that they were randomized to.
    
  